CCL2 and infection: Indeed, low-level viremia begins on day 6 post infection, at which time elevations in systemic proinflammatory mediators such as IL-6 and MCP-1 are detected, and likely contribute to the increased vascular permeability which begins on day 8, and may contribute to mortality commonly observed between days 10 and 12.Thus, in addition to providing a platform for proof-of-concept studies for early stage antiviral drug development, the TCRV AG129 mouse infection model may also be useful to evaluate strategies under consideration for limiting vascular leak due to sepsis[18].